ASSET PURCHASE AGREEMENT


 


This ASSET PURCHASE AGREEMENT is made as of
this 8th day of November, 2018 (this “Agreement”) by and among Vilacto Bio, Inc., a Nevada corporation (“Parent”),
and Vilacto BioIP, LLC, a Nevada limited liability company and wholly owned subsidiary of Parent (together, “Purchaser”),
on the one hand, and 9 Heroes APS, a Denmark corporation on behalf of itself and its Affiliates (as that term is defined below)
(the “Seller”), on the other hand. Purchaser and Seller are sometimes referred to herein individually as a “Party”
and collectively as the “Parties.”


 


RECITALS


 


WHEREAS, the Purchaser desires to purchase
from the Seller and the Seller desires to sell to the Purchaser all of Seller’s rights, title and interest in and to the
Assets (as hereinafter defined), all upon the terms and conditions set forth in this Agreement.


 


NOW, THEREFORE, in consideration of the representations,
warranties and covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto hereby agree as follows:


 


ARTICLE I


CERTAIN DEFINITIONS


 


1.1 CERTAIN DEFINITIONS.


 


(a) The following terms,
when used in this Agreement, shall have the respective meanings ascribed to them below:


 


“ACTION” means
any claim, action, suit, inquiry, hearing, investigation or other proceeding.


 


“AFFILIATE”
means, with respect to a Person, any other Person that, directly or indirectly, through one or more intermediaries, Controls, is
controlled by or is under common Control with, such Person. For purposes of this definition, “CONTROL” (including,
with correlative meanings, the terms “Controlled by” and “under common Control with”) means the possession,
directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through
the ownership of stock, as trustee or executor, by Contract or credit arrangement or otherwise.


 


“AGREEMENT” has the meaning set
forth in the preamble hereto.


 


“ANCILLARY AGREEMENTS” means the
Bill of Sale, the IP Assignment and the Lock-Up Agreement.


 


“ASSETS” has the meaning set forth
in Section 2.1.


 


“BUSINESS DAY” means any day other
than Saturday, Sunday or any day on which banks in Las Vegas, Nevada are required or authorized to be closed.


 


“CLOSING” has the meaning set forth
in Section 3.1.


 


“CLOSING DATE” has the meaning set
forth in Section 3.1.


 




    	 	1	 



    	 



    

 





“COMPETITIVE PRODUCT”
means any product that competes directly with the use, potential use, or expected use of the Assets, or any part thereof, or with
any product currently sold by Purchaser.


 


“CONTRACT”
means any agreement, lease, debenture, note, bond, evidence of Indebtedness, mortgage, indenture, security agreement, option or
other contract or commitment (whether written or oral).


 


“EXCLUDED ASSETS” has the meaning
set forth in Section 2.3.


 


“GAAP” means
United States generally accepted accounting principles as in effect from time to time, consistently applied throughout the specified
period and all prior comparable periods.


 


“GOVERNMENTAL ENTITY”
means any government or political subdivision thereof, whether foreign or domestic, federal, state, provincial, county, local,
municipal or regional, or any other governmental entity, any agency, authority, department, division or instrumentality of any
such government, political subdivision or other governmental entity, any court, arbitral tribunal or arbitrator, and any nongovernmental
regulating body, to the extent that the rules, regulations or orders of such body have the force of Law.


 


“INDEBTEDNESS”
means, as to any Person: (i) all obligations, whether or not contingent, of such Person for borrowed money (including, without
limitation, reimbursement and all other obligations with respect to surety bonds, letters of credit and bankers’ acceptances,
whether or not matured), (ii) all obligations of such Person evidenced by notes, bonds, debentures, capitalized leases or similar
instruments, (iii) all obligations of such Person representing the balance of deferred purchase price of property or services,
(iv) all interest rate and currency swaps, caps, collars and similar agreements or hedging devices under which payments are obligated
to be made by such Person, whether periodically or upon the happening of a contingency, (v) all indebtedness created or arising
under any conditional sale or other title retention Contract with respect to property acquired by such Person (even though the
rights and remedies of the seller or lender under such Contract in the event of default are limited to repossession or sale of
such property), (vi) all indebtedness secured by any Lien on any property or asset owned or held by such Person regardless of whether
the indebtedness secured thereby shall have been assumed by such Person or is non-recourse to the credit of such Person, and (vii)
all indebtedness referred to in clauses (i) through (vi) above of any other Person that is guaranteed, directly or indirectly,
by such Person.


 


        “INTELLECTUAL
PROPERTY” means: all (i) discoveries and inventions (whether patentable or unpatentable and whether or not reduced to practice),
all improvements thereto, and all United States, international, and foreign patents, patent applications (either filed or in preparation
for filing), patent disclosures and statutory invention registrations, including all reissuances, divisions, continuations, continuations
in part, extensions and reexaminations thereof, all rights therein provided by international treaties or conventions, (ii) trademarks,
service marks, trade dress, logos, trade names, corporate names, and other source identifiers (whether or not registered) including
all common law rights, all registrations and applications for registration (either filed or in preparation for filing) thereof,
all rights therein provided by international treaties or conventions, and all renewals of any of the foregoing, (iii) all copyrightable
works and copyrights (whether or not registered), all registrations and applications for registration thereof, all rights therein
provided by international treaties or conventions, and all data and documentation relating thereto, (iv) confidential and proprietary
information, trade secrets, know-how (whether patentable or nonpatentable and whether or not reduced to practice), processes and
techniques, research and development information including patent and/or copyright searches conducted by Seller and/or any third
party, ideas, technical data, designs, drawings and specifications, (v) Software, (vi) coded values, formats, data and historical
or current databases, whether or not copyrightable, (vii) domain names, Internet websites or identities used or held for use by
the Seller, (viii) other proprietary rights relating to any of the foregoing (including without limitation any and all associated
goodwill and remedies against infringements thereof and rights of protection of an interest therein under the laws of all jurisdictions),
and (ix) copies and tangible embodiments of any of the foregoing.


 




    	 	2	 



    	 



    




 


“IP ASSIGNMENT” has the meaning
set forth in Section 3.2(b).


 


“KNOWLEDGE”
means the actual or constructive knowledge after due inquiry of any current officer or manager of the Seller.


 


“LAWS” means
all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of the United States, any
foreign country or any domestic or foreign state, county, city or other political subdivision or of any Governmental Entity.


 


“LIABILITY”
means all Indebtedness, obligations and other Liabilities of a Person, whether absolute, accrued, contingent, fixed or otherwise,
and whether due or to become due (including for Taxes).


 


“LIEN” means
any mortgage, pledge, assessment, security interest, lease, lien, adverse claim, levy, charge or other encumbrance of any kind,
whether voluntary or involuntary (including any conditional sale Contract, title retention Contract or Contract committing to grant
any of the foregoing).


 


“LOSS” means
any and all damages, fines, fees, penalties, deficiencies, losses and expenses (including, without limitation, all interest, court
costs, fees and expenses of attorneys, accountants and other experts or other expenses of litigation or other proceedings or of
any claim, default or assessment).


 


“MATERIAL ADVERSE
EFFECT” means any material adverse effect on the condition, operations, business, prospects or results of sales of the Seller;
PROVIDED, HOWEVER, that any adverse effect arising out of or resulting from the entering into of this Agreement or the consummation
of the transactions contemplated hereby, shall be excluded in determining whether a Material Adverse Effect has occurred.


 


“ORDER” means
any writ, judgment, decree, injunction or similar order of any Governmental Entity (in each case whether preliminary or final).


 


“PERSON” means
any individual, partnership, limited liability company, corporation, association, joint stock company, trust, estate, joint venture,
unincorporated organization, Governmental Entity or any other entity of any kind.


 


“PURCHASE PRICE” has the meaning
set forth in Section 2.1.


 


“PURCHASER” has the meaning set
forth in the preamble hereto.


 


“REPRESENTATIVES”
means, with respect to any Person, the directors, officers, managers, employees, counsel, accountants and other authorized representatives
of such Person.


 


“SELLER” has the meaning set forth
in the preamble hereto.


 


“SOFTWARE”
means all computer software, including source code, object code, machine-readable code, HTML or other markup language, program
listings, comments, user interfaces, menus, buttons and icons, web applications and all files, data, manuals, design notes, research
and development documents, and other items and documentation related thereto or associated therewith.


 




    	 	3	 



    	 



    

 








“SOLVENT” means,
with respect to the Seller, that (a) the Seller is able to pay its Liabilities, as they mature in the normal course of business,
and (b) the fair value of the assets of the Seller is greater than the total amount of Liabilities of the Seller.


 


“TAX RETURNS”
means all returns and reports (including elections, claims, declarations, disclosures, schedules, estimates, computations and information
returns) required to be supplied to a tax authority in any jurisdiction relating to Taxes.


 


“TAXES” means
all federal, state, local and foreign income, profits, franchise, license, social security, transfer, registration, estimated,
gross receipts, environmental, customs duty, capital stock, severance, stamp, payroll, sales, employment, unemployment, disability,
use, property, withholding, excise, production, value added, occupancy and other taxes, duties or assessments of any nature whatsoever
together with all interest, penalties, fines and additions to tax imposed with respect to such amounts and any interest in respect
of such penalties and additions to tax.


 


“THIRD-PARTY CLAIM” has the meaning
set forth in Section 7.2(a).


 


“TRANSFER TAXES”
means all sales, use, value added, excise, registration, documentary, stamps, transfer, real property transfer, recording, gains,
stock transfer and other similar Taxes and fees.


 


(b) For purposes of this
Agreement, except as otherwise expressly provided herein or unless the context otherwise requires: (i) words using the singular
or plural number also include the plural or singular number, respectively, and the use of any gender herein shall be deemed to
include the other genders; (ii) references herein to “Articles,” “Sections,” “subsections”
and other subdivisions without reference to a document are to the specified Articles, Sections, subsections and other subdivisions
of this Agreement; (iii) a reference to a subsection without further reference to a Section is a reference to such subsection as
contained in the same Section in which the reference appears, and this rule shall also apply to other subdivisions within a Section
or subsection; (iv) the words “herein,” “hereof,” “hereunder,” “hereby” and other
words of similar import refer to this Agreement as a whole and not to any particular provision; and (v) the words “include,”
“includes” and “including” are deemed to be followed by the phrase “without limitation.” All
accounting terms used herein and not expressly defined herein shall have the meanings given to them under GAAP.


 


ARTICLE II


PURCHASE AND SALE OF ASSETS


 


2.1 PURCHASE AND SALE OF ASSETS.


 


(a) At the Closing, as
hereinafter defined, Purchaser shall pay Seller for the Assets (the “Purchase Price”)
$3,360,000 USD, payable in 8% secured promissory note equal to $2,000,000 and the balance in common stock in Parent, consisting
of eight million five hundred thousand (8,500,000) shares of Purchaser’s common stock (the “SHARES”), as of the
Closing of this Agreement. The Shares shall be issued bearing a restrictive legend, titled and in denominations as shall be directed
by Seller at Closing. The 8% secured promissory note shall be secured by the assets of Purchaser and convertible into common stock
at the Purchaser’s market price.


 


(b) In consideration of
the payment by the Purchaser of the Purchase Price, the Seller hereby agrees to sell, convey, transfer, assign, grant and deliver
to the Purchaser, and the Purchaser hereby agrees to purchase, acquire and accept from the Seller, at the Closing, all of the Seller’s
right, title and interest in and to all of the Assets, free and clear of all Liens. The Assets will be transferred and held in
Vilacto BioIP, LLC. The term “ASSETS” means all Domain Names, websites and Intellectual Property of Seller as set forth
on Schedule 4.6 attached hereto.


 




    	 	4	 



    	 



    




 


2.2 ASSUMPTION OF LIABILITIES. For greater
certainty, the Purchaser assumes no Liabilities relating to the Assets of the Seller or the Seller’s business (including
Tax Liabilities) except as are expressly set forth on Schedule 2.2.


 


2.3 EXCLUDED ASSETS. All other assets of Seller
other than the Assets.


 


ARTICLE III


THE CLOSING


 


3.1 CLOSING. The closing of the transactions
contemplated hereby (the “CLOSING”) shall take place on November 8, 2018, at 11:59PM at the offices of the Purchaser
(the “CLOSING DATE”).


 


3.2 DELIVERY OF ITEMS BY THE SELLER. The Seller
shall deliver to the Purchaser at the Closing the items listed below:


 


(a) an Intellectual Property
Assignment, duly executed by the Seller, in the form attached hereto as Exhibit A (the “IP ASSIGNMENT”);


 


(b) written letter of instructions
to Purchaser, specifying the names and denominations in which the Shares are to be delivered, executed by all Sellers, together
with tax identification numbers and mailing addresses for each recipient; and


 


(c) such other documents
and instruments as the Purchaser may reasonably request.


 


3.3 DELIVERY OF ITEMS BY THE PURCHASER. The
Purchaser shall deliver to the Seller at the Closing the items listed below:


 


		(a)	the $2,000,000 demand promissory note; 



 


		(b)	the Shares; and



 


(b) such other documents
and instruments as the Seller may reasonably request.


 


ARTICLE IV


REPRESENTATIONS AND WARRANTIES OF THE SELLER


 


As an inducement to the Purchaser to enter
into this Agreement, Seller represents and warrants to the Purchaser as follows:


 


4.1 AUTHORIZATION. The Seller has full power
and authority to execute and deliver this Agreement and the Ancillary Agreements, as applicable, and to perform its obligations
hereunder and thereunder. This Agreement and the Ancillary Agreements have been duly executed and delivered by the Seller and,
assuming the due authorization, execution and delivery hereto and thereof by the Purchaser, constitute the valid and legally binding
obligations of the Seller enforceable in accordance with their respective terms.


 


4.2 BROKERS’ FEES. No agent, broker,
finder, investment banker, financial advisor or other similar Person will be entitled to any fee, commission or other compensation
in connection with any of the transactions contemplated by this Agreement on the basis of any act or statement made or alleged
to have been made by the Seller, any of its Affiliates, or any investment banker, financial advisor, attorney, accountant or other
Person retained by or acting for or on behalf of the Seller or any such Affiliate.


 




    	 	5	 



    	 



    




 


4.3 NONCONTRAVENTION. Neither the execution,
delivery or performance of this Agreement or the Ancillary Agreements, as applicable, nor the consummation of the transactions
contemplated hereby or thereby will, with or without the giving of notice or the lapse of time or both, (i) violate any Law or
Order or other restriction of any Governmental Entity to which the Seller may be subject or (ii) conflict with, result in a breach
of, constitute a default under, result in the acceleration of any right or obligation under, create in any party the right to accelerate,
terminate, modify, cancel, require any notice under or result in the creation of a Lien on any of the Assets under, any Contract
to which the Seller is a party or by which it is bound and to which any of its Assets is subject.


 


4.4 LITIGATION. There is no pending or, to
the Knowledge of the Seller, threatened Action against or affecting the Assets except as outlined in Schedule 4.4. Neither the
Seller nor the Assets are subject to any Order restraining, enjoining or otherwise prohibiting or making illegal any action by
the Seller, this Agreement or any of the transactions contemplated hereby. See Schedule 4.4 for relevant Seller disclosures.


 


4.5 CONTRACTS. Except as disclosed on Schedule
4.5, there are no executory Contracts (whether license agreements, development agreements or otherwise), to which any of the Assets
are bound or subject (other than this Agreement).


 


4.6 INTELLECTUAL PROPERTY.


 


Seller represents and warrants that:


 


(a) Schedule 4.6 contains
a list of all patents, trade names, trademarks and/or copyrights and all applications therefor owned by Seller with respect to
the Assets and all licenses, if any, relating to the foregoing patents, trade names, trademarks and/or copyrights and all applications
therefor. Schedule 4.6 identifies the owner of each item listed thereon and, in the case of registrations and applications, the
application or registration number and date. The Seller has not taken any action that could result in any of the registrations
and applications for registration for the Assets not being valid and in full force and effect.


 


(b) Except as disclosed
on Schedule 4.6, the Seller is the sole and exclusive owner of, and has good and marketable title to, all of the Intellectual Property
in and to the Assets, including the Intellectual Property set forth on Schedule 4.6, free and clear of all Liens. Except as disclosed
on Schedule 4.6, the Seller has sole and exclusive right to develop, perform, use, create derivative works of, operate, reproduce,
market, sell, license, display, distribute, publish and transmit the Intellectual Property in and to the Assets. Upon the Closing,
except as disclosed on Schedule 4.6, the Purchaser will have sole and exclusive right, title and interest in and to the Intellectual
Property in and to the Assets, such that the Purchaser shall thereafter have sole and exclusive rights to perform, reproduce, create
derivative works of, develop, use, operate, market, sell, license, display, publish, transmit and distribute the Assets, free of
all encumbrances. The Seller has taken reasonable measures to protect the proprietary nature of the Intellectual Property in and
to the Assets and to maintain in confidence the trade secrets and confidential information that it owns or uses. Except as disclosed
on Schedule 4.6, no other Person has any rights to any of Intellectual Property in and to the Assets and, to the knowledge of the
Seller, no other Person is infringing, violating or misappropriating any of the Intellectual Property in and to the Assets.


 


(c) With respect to the
Seller’s Intellectual Property contributed to the Assets, such Intellectual Property does not infringe upon, violate or constitute
a misappropriation of any Intellectual Property or other right of any other Person. In addition, to Seller’s knowledge, none
of the activities or business presently conducted by the Seller with respect to the Assets infringes or violates, or constitutes
a misappropriation of, any Intellectual Property or other right of any other Person. Neither the Seller nor any Affiliate of the
Seller has received any written complaint, claim or notice alleging any such infringement, violation or misappropriation. Further,
neither the Seller nor any Affiliate of the Seller has disclosed to any Person, any product formula or design, or any portion or
aspect of any product formula or design, which is part of the Assets, including the Intellectual Property.


 




    	 	6	 



    	 



    

 





ARTICLE V


REPRESENTATIONS AND WARRANTIES OF THE PURCHASER


 


As an inducement to the Seller to enter into
this Agreement, the Purchaser represents and warrants to the Seller as follows:


 


5.1 AUTHORIZATION. The Purchaser has full power
and authority to execute and deliver this Agreement and the Ancillary Agreements, as applicable, and to perform its obligations
hereunder and thereunder. This Agreement and the Ancillary Agreements have been duly executed and delivered by the Purchaser and,
assuming the due authorization, execution and delivery hereof and thereof by the Seller, constitute the valid and legally binding
obligations of the Purchaser enforceable in accordance with their respective terms. Purchaser is a corporation organized under
the laws of the State of Nevada, in good standing, and has obtained all consents and other approvals necessary under Nevada law,
its Articles of Incorporation, and its Bylaws necessary for the execution, delivery and performance of this Agreement and the Ancillary
Agreements.


 


5.2 NONCONTRAVENTION.


 


(a) Neither the execution,
delivery or performance of this Agreement or the Ancillary Agreements, as applicable, nor the consummation of the transactions
contemplated hereby or thereby will, with or without the giving of notice or the lapse of time or both, violate any Law or Order
or other restriction of any Governmental Entity to which the Purchaser may be subject.


 


(b) The execution and delivery
of this Agreement and the Ancillary Agreements, as applicable, by the Purchaser does not, and the performance of this Agreement
and the Ancillary Agreements by the Purchaser and the consummation of the transactions contemplated hereby and thereby will not,
require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Entity.


 


5.3 BROKERS’ FEES. No agent, broker,
finder, investment banker, financial advisor or other similar Person will be entitled to any fee, commission or other compensation
in connection with any of the transactions contemplated by this Agreement on the basis of any act or statement made or alleged
to have been made by the Purchaser, any of its Affiliates, or any investment banker, financial advisor, attorney, accountant or
other Person retained by or acting for or on behalf of the Purchaser or any such Affiliate.


 


ARTICLE VI


CONDITIONS TO OBLIGATION TO CLOSE


 


6.1 CONDITIONS TO CLOSING BY THE PURCHASER.
The obligation of the Purchaser to effect the transactions contemplated hereby is subject to the satisfaction or waiver by the
Purchaser of the following conditions:


 


(a) The representations
and warranties of certain of the Seller set forth in this Agreement shall be true and correct in all material respects, with respect
to representations and warranties not qualified by materiality, or in all respects, with respect to representations and warranties
qualified by materiality, as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date.


 




    	 	7	 



    	 



    

 





(b) The Seller shall have
performed in all material respects the covenants required to be performed by it under this Agreement at or prior to the Closing
Date.


 


(c) The Seller shall have
executed and delivered each of the Ancillary Agreements, as applicable.


 


(d) There shall be no effective
or pending Law or Order that would prohibit the Closing, and the Seller shall have obtained all necessary approvals of any Governmental
Entities in connection with the transactions contemplated hereby and by the Ancillary Agreements.


 


(e) The Seller shall have
delivered each of the items described in Section 3.2.


 


(f) Seller shall not have
made changes to current levels of compensation unless agreed upon by the Parties or paid any dividends prior to the Close.


 


(g) Seller shall have conducted
its business only in the ordinary course and shall not have acquired or agreed to acquire as part of the business all or any substantial
portion of the assets or business of any other business organization by merger or consolidation, stock purchase or asset purchase
without Purchaser’s approval in writing.


 


(h) Seller shall have completed
the approval of this Agreement and Ancillary Agreements as required under its articles of organization, operating agreements, and
the laws of the jurisdictions where it is subject.


 


(i) There were no appraisal
rights (dissenter’s rights) asserted by any owner of Seller in connection with this transaction.


 


6.2 CONDITIONS TO CLOSING
BY THE SELLER. The obligation of the Seller to effect the transactions contemplated hereby is subject to the satisfaction or waiver
by the Seller of the following conditions:


 


(a) The representations
and warranties of the Purchaser set forth in this Agreement shall be true and correct in all material respects, with respect to
representations and warranties not qualified by materiality, and in all respects, with respect to representations and warranties
qualified by materiality, in each case as of the date of this Agreement and as of the Closing Date as though made on and as of
the Closing Date.


 


(b) The Purchaser shall
have performed in all material respects the covenants required to be performed by it under this Agreement at or prior to the Closing
Date.


 


(c) The Purchaser shall
have executed and delivered each of the Ancillary Agreements, as applicable.


 


(d) There shall be no effective
or pending Law or Order that would prohibit the Closing, and the Purchaser shall have obtained all necessary approvals of any Governmental
Entities in connection with the transactions contemplated hereby and by the Ancillary Agreements.


 


(e) The Purchaser shall have delivered each
of the items described in Section 3.3.


 




    	 	8	 



    	 



    




 


ARTICLE VII


POST-CLOSING COVENANTS


 


7.1 TRANSFER TAXES. Notwithstanding anything
herein to the contrary, Purchaser shall be liable for and shall pay any Transfer Taxes or other similar tax imposed in connection
with the transfer of the Assets pursuant to this Agreement. The party responsible under applicable Law for remitting any such tax
shall pay and remit such tax on a timely basis and, if such party is the Seller, the Seller shall notify the Purchaser of the amount
of such tax, and the Purchaser shall promptly pay to the Seller the amount of such tax.


 


7.2 FURTHER ACTION. From and after the Closing
each of the parties hereto shall execute and deliver such documents and take such further actions as may reasonably be required
to carry out the provisions of this Agreement and the Ancillary Agreements and to give effect to the transactions contemplated
hereby and thereby, including to give the Purchaser effective ownership and control of the Assets.


 


7.3 ACCOUNTING. Purchaser will appoint an accounting
firm of its choosing to maintain Sellers’ financial records to ensure compliance with US GAAP. Within 71 days of Closing,
Seller shall provide Purchaser with an audit for the two latest fiscal year periods and reviewed financials for an interim period
ending September 30, 2018 prepared by Seller’s independent auditor, satisfactory to Purchaser.


 


ARTICLE VIII


MISCELLANEOUS


 


8.1 SURVIVAL. Notwithstanding any right of
the Purchaser (whether or not exercised) to investigate the affairs of the Seller or any right of any party (whether or not exercised)
to investigate the accuracy of the representations and warranties of the other party contained in this Agreement or the waiver
of any condition to Closing, each of the parties hereto has the right to rely fully upon the representations, warranties, covenants
and agreements of the other contained in this Agreement. The representations, warranties, covenants and agreements of the parties
hereto contained in this Agreement and any certificate or other document provided hereunder or thereunder will survive the Closing.


 


8.2 NO THIRD-PARTY BENEFICIARIES. The terms
and provisions of this Agreement are intended solely for the benefit of the Parties hereto and their respective successors and
permitted assigns, and it is not the intention of the Parties to confer third-party beneficiary rights, and this Agreement does
not confer any such rights, upon any other Person.


 


8.3 ENTIRE AGREEMENT. This Agreement (including
the Exhibits and the Schedules hereto) constitute the entire agreement between the Parties hereto with respect to the subject matter
hereof and thereof and supersede any prior understandings, agreements or representations by or between the Parties hereto, written
or oral, with respect to such subject matter.


 


8.4 SUCCESSION AND ASSIGNMENT. This Agreement
shall be binding upon and inure to the benefit of the Parties named herein and their respective successors and permitted assigns.
No Party hereto may assign either this Agreement or any of its rights, interests or obligations hereunder without the prior written
approval of the other Parties hereto.


 




    	 	9	 



    	 



    

 





8.5 DRAFTING. The Parties have participated
jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation
arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise
favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.


 


8.6 GOVERNING LAW. This Agreement shall be
governed by, and construed in accordance with, the laws of the State of Nevada, without giving effect to any choice of law or conflict
of law provision or rule that would cause the application of the Laws of any jurisdiction other than the State of Nevada.


 


8.7 AMENDMENTS AND WAIVERS. No amendment of
any provision of this Agreement shall be valid unless such amendment is in writing and signed by each of the Parties hereto. No
waiver by any Party hereto of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or
not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder
or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. No waiver shall be valid unless such
waiver is in writing and signed by the Party against whom such waiver is sought to be enforced.


 


8.8 SEVERABILITY. If any provision of this
Agreement is held to be illegal, invalid or unenforceable under any present or future Law, and if the rights or obligations of
any Party hereto under this Agreement will not be materially and adversely affected thereby, (a) such provision will be fully severable,
(b) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a
part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the
illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable
provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in
terms of such illegal, invalid or unenforceable provision as may be possible.


 


8.9 EXPENSES. Except as otherwise expressly
set forth herein or therein, each of the Parties hereto will bear its own costs and expenses (including legal fees and expenses)
incurred in connection with this Agreement, the Ancillary Agreements and the transactions contemplated hereby or thereby, whether
or not the transactions contemplated hereby or thereby are consummated.


 


8.10 INCORPORATION OF EXHIBITS AND SCHEDULES.
The Exhibits, Annexes and Schedules identified in this Agreement are incorporated herein by reference and made a part hereof. Unless
otherwise specified, no information contained in any particular numbered Schedule shall be deemed to be contained in any other
numbered Schedule unless explicitly included therein (by cross reference or otherwise).


 


8.11 SPECIFIC PERFORMANCE. The Parties hereto
agree that irreparable damage would occur in the event that any provision of this Agreement was not performed in accordance with
the terms hereof and that the Parties shall be entitled to specific performance of the terms hereof in addition to any other remedy
available to them at law or equity.


 


8.12 HEADINGS. The descriptive headings contained
in this Agreement are included for convenience of reference only and shall not affect in any way the meaning or interpretation
of this Agreement.


 


8.13 COUNTERPARTS. This Agreement may be executed
in one or more counterparts, and by the different Parties hereto in separate counterparts, each of which when executed shall be
deemed to be an original but all of which taken together shall constitute one and the same agreement.


 


8.14 CONFIDENTIALITY. This Exhibits and Schedules
of this Agreement shall remain strictly CONFIDENTIAL among The Parties. No discloser of the information contained herein or associated
Agreements and Schedules may take place without the express and written consent of The Parties and their represented signees as
designated below. Except as required by law.





 





[Signature page follows]


 




    	 	10	 



    	 



    

 


IN
WITNESS WHEREOF, the Parties hereto have duly executed this Agreement as of the date first written above.


 


PURCHASER


 


Vilacto
Bio, Inc. 






By: /s/ Gert Andersen

Name: Gert Andersen

Title: CEO


 


Vilacto
BioIP, LLC


 


 


By:
/s/ Gert Andersen

Name: Gert Andersen


Title:
Manager


 


SELLER



9 Heroes APS


 


 


By:
/s/ Gert Andersen

Name: Gert Andersen

Title: CEO


 




    	 	11	 



    	 



    

 





EXHIBIT A


 


IP ASSIGNMENT


 


This Intellectual Property
Assignment (the “Assignment”) is made as of November 8, 2018 by and between Vilacto Bio, Inc., a Nevada
corporation (“Parent”), and Vilacto BioIP, LLC, a Nevada limited liability company and wholly owned subsidiary of
Parent (“Assignee”), on the one hand, and 9 Heroes APS, a Denmark corporation (“Assignor”), on the
other hand.  


 


1.     Intellectual
Property Assignment. Assignor hereby assigns to Assignee, its successors and assigns, for good and sufficient consideration
in connection with execution of the Asset Purchase Agreement dated November 8, 2018, the entire right, title and interest in and
to any and all of the following that exist as of the date hereof: (a) Intellectual Property (as defined in the Asset Purchase Agreement)
relating to Assignor (b) any and all Intellectual Property Rights (defined below) claiming or covering such Intellectual Property
and (c) any and all causes of action that may have accrued to the undersigned in connection with such Intellectual Property and/or
Intellectual Property Rights.  Assignor further agrees to execute and deliver the Patent Assignment Agreement as attached
hereto as Annex “A.”


 


2.     Intellectual
Property Rights Definition. “Intellectual Property Rights” means, collectively, all rights in, to and under the
Intellectual Property.


 


4.     Prior
Inventions. The Assignor has listed in Annex “B” all inventions, original works of authorship, developments, improvements,
and trade secrets which were made by the Assignor prior to the date hereof, (collectively, the “Prior Inventions”),
which belong to the Assignor, which relate to Assignor’s proposed or current business, products or research and development,
and which are not being assigned to Assignee; or, if no such list is attached, the Assignor represents that there are no such inventions.
 In the event that any Prior Inventions are listed on Exhibit B, the Assignor hereby grants to Assignor a present, non-exclusive,
royalty free, irrevocable, perpetual, world-wide license to make, have made, sublicense, modify, use and sell such Prior Invention
as part of or in connection with Assignor’s products and technology currently under development or in production.  


 


5.     Further
Assurances. Assignor agrees to execute any and all papers and documents, and take such other actions as are reasonably requested
by Parent, to evidence, perfect, defend the foregoing assignment and fully implement Assignor’s proprietary rights in the
subject matter assigned hereunder, such as obtaining and enforcing copyrights, patents or trademarks and to fully cooperate in
the prosecution, enforcement and defense of such proprietary rights.  Assignor further agrees that if Parent or Assignee is
unable, for any reason, to secure signatures to apply for or to pursue any application for any patent, copyright, trademark or
other proprietary right covering any Intellectual Property assigned to Assignee above, then Assignor hereby irrevocably designates
and appoints Assignee’s duly authorized agent as Assignor’s agent and attorney-in-fact, to act for and in Assignor’s
behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution
and issuance of patents, copyrights, trademarks and other registrations thereon with the same legal force and effect as if executed
by Assignor.  


 


6.     Representations
and Covenants. The Assignor represents and warrants that (i) the Assignor is the owner of the entire right, title and interest
in and to the Intellectual Property, (ii) the Assignor has the sole right and authority to enter into this Assignment and grant
the rights hereunder, and (iii) the Assignor has not previously granted any rights or licenses in the Intellectual Property.     


 


7.     Governing
Law. This Assignment and actions taken hereunder shall be governed by, and construed in accordance with the laws of the State
of Nevada applied without regard to conflict of law principles.


 


8.     Miscellaneous.
If any one or more provisions contained in this Assignment shall, for any reason, be held to be invalid, illegal, or unenforceable
in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Assignment, but this
Assignment shall be construed as if such invalid, illegal, or unenforceable provision had never been contained herein.  The
terms and provisions of this Assignment may be modified or amended only by written agreement executed by all parties hereto.


 


[Signature page follows]


 




    	 	12	 



    	 



    

 





IN WITNESS WHEREOF, the undersigned
has caused this Intellectual Property Assignment to be executed.


 


PARENT


 


Vilacto Bio, Inc. 






By: /s/ Gert Andersen

Name: Gert Andersen


Title: CEO


 


ASSIGNEE


 


Vilacto BioIP, LLC


 


 


By: /s/ Gert Andersen

Name: Gert Andersen


Title: Manager


 


ASSIGNOR



9 Heroes APS


 


 


By: /s/ Gert Andersen

Name: Gert Andersen

Title: CEO


 




    	 	13	 



    	 



    

 





Annex A


Patent Assignment Agreement


 


Whereas, 9 Heroes APS (the “Assignor”) a Limited
Liability Company, is the owner of the entire right, title and interest in, and to:


 


• United States Patent Application # 8,637,075 entitled
“Colostrum Composition”


• European Patent Application # EP2341916 entitled “Colostrum
Composition”


• Hong Kong Patent Application # HK1159997 entitled “Colostrum
Composition”


• Canada Patent Application # 2,773,277 entitled “Colostrum
Composition”


 


and of the invention therein described; and


 


Whereas, Vilacto BioIP, LLC, (the
“Company”) a limited liability company organized and existing under the laws of the State of Nevada, United
States of America, and having a place of business at Fabriksvej 48 4700 Naestved, Denmark, is desirous of obtaining the
entire right, title and interest in, to and under such patent applications, and such invention.


 


Now, therefore, in consideration acknowledged
above to Assignor in hand paid, and other good and valuable consideration, the receipt of which is hereby acknowledged, Assignor
has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto Company,
its successors, legal representatives and assigns, the entire right, title and interest in, to and under the invention, including
the right to sue for past infringement, and all patents of the United States which may be granted thereon and all reissues and
extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for
patents, utility models, and designs which have already been and which may hereafter be filed for the invention in any country
or countries foreign to the United States, together with the right to file such applications and the right to claim for the same
the priority rights derived from the patent under the patent laws of the United States, the International Convention for the Protection
of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application
is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility
models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the
United States and all extensions, renewals and reissues thereof; and


 


Assignor Hereby authorizes and requests
the Commissioner of Patents and Trademarks of the United States, and any official of any country or countries foreign to the United
States, whose duty it is to issue patents to issue the same to Company, its successors, legal representatives and assigns, in accordance
with the terms of this instrument; and


 


Assignor Hereby covenants and agrees that
it has the full right to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute,
any agreement in conflict herewith; and


 


Assignor Hereby further covenants and agrees
that Assignor will communicate to Company, its successors, legal representatives and assigns, any material facts known to Assignor
respecting the invention, and generally do everything possible to aid Company, its successors, legal representatives and assigns,
to obtain and enforce proper protection for the invention in all countries.


 


[Signature page follows]


 




    	 	14	 



    	 



    

  


IN WITNESS AND IN TESTIMONY WHEREOF, I,
hereunto set my hand and seal this 29th of June, 2016.


 


9 Heroes APS


 


 


/s/ Gert Andersen


Name: Gert Andersen


Title: CEO


 


 


Vilacto BioIP, LLC


 


 


/s/ Gert Andersen


Name: Gert Andersen

Title: Manager


 


[For Patents, a proper assignment must be
made at the USPTO Office within 3 months of executing this agreement which can be done electronically at http://epas.uspto.gov/]


 




    	 	15	 



    	 



    







 


Annex B


Prior Inventions





 




    	 	16	 



    	 



    

 


SCHEDULE 2.2


 


ASSUMED LIABILITIES


 


None.


 




    	 	17	 



    	 



    

 


Schedule 4.4 – Seller Litigation Disclosures


 


None.


 




    	 	18	 



    	 



    

  


SCHEDULE 4.5


 


None. 


 




    	 	19	 



    	 



    

 


SCHEDULE 4.6


 


INTELLECTUAL PROPERTY


 


• United States Patent Application # 8,637,075 entitled “Colostrum
Composition”


• European Patent Application # EP2341916 entitled “Colostrum
Composition”


• Hong Kong Patent Application # HK1159997 entitled “Colostrum
Composition”


• Canada Patent Application # 2,773,277 entitled “Colostrum
Composition”


 


The patent portfolio covers a product against Psoriasis, which is
under development. According to the company, the product will be marketed in 2019 and will be covered by the patent applications
until 2029.


 








    	 	20